Hydroxynorketamine
- Generic Name
- Hydroxynorketamine
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
Phase 1
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 74
- Registration Number
- NCT04711005
- Locations
- 🇺🇸
Duke Early Phase Clinical Research, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath